A new depression drug has received the green light from the U.S. Food and Drug Administration after years of development by two Cambridge drugmakers. Zuranolone, a new drug co-developed by Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics Inc. (Nasdaq: SAGE), scored an FDA approval late Friday — but the approval was only for postpartum depression, not major depressive disorder. The companies had applied to market the drug as a treatment for both.
